However, co-treatment with the ABCB1/MDR1/P-GP efflux pump inhibitor verapamil led to increased response of IDH1-mut cells to venetoclax compared to IDH1-wt cells (Supplementary Fig. S4), suggesting that blockade of the ABCB1/MDR1/P-GP efflux pump may be specifically relevant for the clinically benefit of Venetoclax treatment in IDH1-mut AML. Here, PGP is linked to acute myeloid leukemia.